^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

B001

i
Other names: B001, B-001
Associations
Company:
Shanghai Pharma
Drug class:
CD20 inhibitor
Related drugs:
Associations
6ms
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) (clinicaltrials.gov)
P2/3, N=132, Not yet recruiting, Shanghai Jiaolian Drug Research and Development Co., Ltd
New P2/3 trial
|
B001
6ms
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) (clinicaltrials.gov)
P1, N=45, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial primary completion date: Apr 2024 --> Dec 2024
Trial primary completion date
|
B001
11ms
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) (clinicaltrials.gov)
P1, N=45, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
Trial completion date • Trial primary completion date
|
B001
3years
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=30, Completed, Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting --> Completed
Clinical • Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
B001